Oragenics (NYSEAMERICAN:OGEN) Now Covered by StockNews.com

StockNews.com began coverage on shares of Oragenics (NYSEAMERICAN:OGEN) in a report released on Friday. The brokerage issued a sell rating on the biotechnology company’s stock.

Oragenics Price Performance

Shares of NYSEAMERICAN:OGEN opened at $3.12 on Friday. The business’s 50-day moving average is $3.41 and its 200-day moving average is $3.71. Oragenics has a 1 year low of $2.60 and a 1 year high of $19.06.

Oragenics (NYSEAMERICAN:OGEN) last issued its earnings results on Monday, August 14th. The biotechnology company reported ($1.51) EPS for the quarter. The company had revenue of $0.01 million during the quarter.

Hedge Funds Weigh In On Oragenics

Institutional investors have recently modified their holdings of the business. State Street Corp lifted its stake in Oragenics by 8.1% in the first quarter. State Street Corp now owns 495,563 shares of the biotechnology company’s stock valued at $171,000 after purchasing an additional 37,338 shares during the last quarter. Renaissance Technologies LLC lifted its stake in Oragenics by 116.5% in the second quarter. Renaissance Technologies LLC now owns 209,600 shares of the biotechnology company’s stock valued at $73,000 after purchasing an additional 112,800 shares during the last quarter. Finally, Millennium Management LLC lifted its position in shares of Oragenics by 591.6% during the second quarter. Millennium Management LLC now owns 128,733 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 110,119 shares in the last quarter. 2.07% of the stock is owned by institutional investors.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.